LXEO
Lexeo Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Apertura Gene Therapy grants Lexeo Therapeutics access to TfR1 CapX for a Friedreich ataxia gene therapy programSep 23, 2026
- Lexeo Therapeutics received FDA RMAT designation for LX2020 in PKP2 arrhythmogenic cardiomyopathyAug 6, 2026
- Lexeo Therapeutics announced positive interim Phase I/II data for LX2020 in cardiomyopathyJan 12, 2026
- Lexeo Therapeutics announces progress in FDA discussions for accelerated approval pathway and positive interim clinical data for LX2006 in Friedreich ataxia cardiomyopathyOct 7, 2025
- Lexeo Therapeutics announces FDA Breakthrough Therapy designation for LX2006 in Friedreich ataxiaJul 11, 2025